Founded in France in 1999, the Cellectis group is based on highly specific DNA engineering technologies. Its application sectors are human health, agriculture and bio-energies. Co-created by André Choulika, its Chief Executive Officer, Cellectis SA is today one of the world leading companies in the field of genome engineering. The Group has a workforce of 230 employees working on 5 sites worldwide: Paris & Evry in France, Gothenburg in Sweden, St Paul (Minnesota) & Cambridge (Massachusetts) in the United States.

The Cellectis group achieved revenues of Eur16M in 2011 and has since its inception has signed more than 80 industrial agreements with pharmaceutical, agrochemical, and biotechnology companies. AFM, DuPont, BASF, Bayer, Total, Limagrain, and Novo Nordisk are some of the Group’s clients and partners. Since 2007, Cellectis SA has been listed on NYSE-Euronext Alternext market (code: ALCLS) in Paris. Cellectis SA has developed, owns and or controls technologies for transgenesis and targeting of genes and in particular, but not limited to, technologies consisting in the specific deletion, substitution or insertion of genomic sequences and technologies relating to meganucleases such as I-SceI enzyme, TALEN™, designed to target genomic sequences of interest in vivo or ex vivo, ranging from natural, custom-made nucleases and to ready-to-use genomic recombination systems.

Cellectis therapeutics is a subsidiary of Cellectis SA. Its aim is innovative strategies for the evelopment of widereaching therapeutic treatments based on core Cellectis SA’s technology. Cellectis therapeutics has on-going projects in monogenetic diseases (e.g. myopathies, hemoglobinopathies, hemophilia), as well as a continuing antiviral program for the prevention of recurrent Herpes virus (HSV-1) infection during corneal transplantation.

However, in 2011, Cellectis therapeutics initiated a program aimed at engineering T lymphocytes, considering this a key therapeutic application of genome engineering technology. This is currently the primary focus of Cellectis Therapeutics. In addition, the recent acquisition of Cytopulse’s scalable electroporation technology by Cellectis SA has allowed Cellectis therapeutics to develop robust methods for non-viral vectorization of nucleases in hematopoietic cells. This allows the efficient modification of endogenous genomic sequences of primary T lymphocytes, thereby laying the foundation for the development of Cellectis therapeutics’ program for adoptive immunotherapy. Cellectis therapeutics has developed processes for T cell engineering in cancer indications and is committed to development of T cell based therapies.